Clinical Trial Update: Losartan to Reverse Sickle Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating losartan for reversing sickle cell nephropathy has completed enrollment with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephropathy
• Sickle Cell Disease

Drugs mentioned

• Losartan (losartan)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Nephropathy, Sickle Cell Anemia | Phase 2 | Status: COMPLETED | Results posted: 2020-09-29